REVIVA PHARMA HLDGS INC
RVPH
RVPH was delisted on the 13th of May, 2026.
28 hedge funds and large institutions have $21M invested in REVIVA PHARMA HLDGS INC in 2024 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 12 increasing their positions, 5 reducing their positions, and 11 closing their positions.
209% more call options, than puts
Call options by funds: $2.19M | Put options by funds: $709K
140% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 5
1.1% more ownership
Funds ownership: 18.86% → 19.96% (+1.1%)
22% less funds holding
Funds holding: 36 → 28 (-8)
23% less capital invested
Capital invested by funds: $27.1M → $21M (-$6.11M)
73% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
+$3.7M |
| 2 |
SSA
Schonfeld Strategic Advisors
New York
|
+$3.28M |
| 3 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
+$2M |
| 4 |
Millennium Management
New York
|
+$209K |
| 5 |
Focus Partners Wealth
Boston,
Massachusetts
|
+$198K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$9.08M |
| 2 |
RA
Rosalind Advisors
Toronto,
Ontario, Canada
|
-$1.01M |
| 3 |
Man Group
London,
United Kingdom
|
-$253K |
| 4 |
Two Sigma Investments
New York
|
-$214K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$196K |
RVPH Hedge Fund Activity: Q1 2024 in Review
28 of the 6,961 institutional investors tracked by Wall St. Rank reported a position in REVIVA PHARMA HLDGS INC (RVPH) for Q1 2024, worth a combined $21M — down 23% from $27.1M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of RVPH and 3 opened new positions — a net loss of 8 holders — while 5 trimmed existing stakes and 12 added.
The largest buyer was Woodline Partners, adding an estimated $3.7M. The largest seller was Armistice Capital, exiting entirely with an estimated $9.08M sold.
- 28 institutional investors held REVIVA PHARMA HLDGS INC (RVPH) as of Q1 2024, down from 36 in Q4 2023.
- Funds reported $21M of REVIVA PHARMA HLDGS INC stock for Q1 2024, down 23% quarter-over-quarter.
- 3 funds opened new REVIVA PHARMA HLDGS INC positions in Q1 2024 and 11 closed out, a net change of -8 holders.
- The largest REVIVA PHARMA HLDGS INC buyer in Q1 2024 was Woodline Partners, an estimated $3.7M added.
- The largest REVIVA PHARMA HLDGS INC seller in Q1 2024 was Armistice Capital, an estimated $9.08M sold.
Based on aggregated 13F filings for Q1 2024.